by Robert Solomon | Jan 7, 2020 | Indirect Spend, Industry Big Data, Industry Catalog, Matchmaking, Procure to Pay
There’s a battle being waged over Life Sciences R&D spend. Why should we care? It’s a huge market. The global pharmaceutical industry spends about $200 billion annually on R&D and the market grows faster than GDP. About $70 billion of this is...
by Robert Solomon | Sep 30, 2016 | Indirect Spend, Industry Cloud, Procure to Pay
New Year’s Day should be in the fall, not January. After all, fall is when: we have a change of season, the new school year starts, Muslims and Jews are already celebrating the New Year, the harvest comes in, etc. Apparently, fall is also the new year for...
by Robert Solomon | May 31, 2016 | B2B Software, Procure to Pay, Public Sector, Valuation
The Wall Street Journal is reporting that Sciquest (SQI) has agreed to be taken private by Accel-KKR for $17.75 per share or about $509 million. This represents a 34% premium to the stock’s closing price on Friday. According to the WSJ, “SciQuest’s board...
by Robert Solomon | May 18, 2015 | B2B Software
Basware is a public company listed on the Helsinki exchange. Though I have included the company in some previous blog posts (here and here), I have not, until now, given the company its due. Basware can, oversimplistically, be thought of as a procure-to-pay suite...
by Robert Solomon | Apr 7, 2015 | B2B Software, Enterprise Software, Procure to Pay
I was not planning any more posts on Procure-to-Pay suites, but then Gartner issued their Magic Quadrant on the market. I felt compelled to revisit the topic in one, very simple way: through an investor’s lens. It is rare that so many key players in a...
Recent Comments